FS
FSPKF.US Fisher & Paykel Healthcare Corporation Limited
- Market cap
- USD 15.9B
- P/E
- 57.4x
- P/B
- 13.39x
- ROE
- 22.1%
- Dividend yield
- 1.10%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is FSPKF.US undervalued?
Graham numberThe Graham number of Fisher & Paykel Healthcare Corporation Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fisher & Paykel Healthcare Corporation Limited fundamental analysis
No fundamental analysis for Fisher & Paykel Healthcare Corporation Limited yet.
Fisher & Paykel Healthcare Corporation Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow na…
Full company profileFisher & Paykel Healthcare Corporation Limited financial statements
Fisher & Paykel Healthcare Corporation Limited annual financial statements (NZD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 870M | 965M | 1.07B | 1.27B | 1.95B | 1.64B | 1.59B | 1.76B | 1.28B | 2.36B |
| Gross Profit | 566M | 634M | 718M | 846M | 1.22B | 1.01B | 946M | 1.06B | 530M | 1.52B |
| Operating Income | 281M | 316M | 338M | 374M | 723M | 509M | 335M | 254M | -371M | 674M |
| EBITDA | 281M | 316M | 338M | 435M | 808M | 605M | 434M | 368M | 654M | 834M |
| Net Income | 169M | 190M | 209M | 287M | 524M | 377M | 250M | 133M | 377M | 473M |
| EPS | 0.30 | 0.33 | 0.36 | 0.50 | 0.91 | 0.65 | 0.43 | 0.23 | 0.64 | 0.80 |
| Balance Sheet | ||||||||||
| Total Assets | 957M | 1.09B | 1.26B | 1.44B | 2.08B | 2.11B | 2.20B | 2.28B | 2.55B | 2.88B |
| Total Liabilities | 236M | 280M | 306M | 461M | 554M | 427M | 451M | 523M | 660M | 746M |
| Shareholders' Equity | 721M | 808M | 951M | 974M | 1.52B | 1.68B | 1.75B | 1.76B | 1.89B | 2.14B |
| Cash & Short-term Investments | 66.7M | 140M | 147M | 145M | 378M | 290M | 121M | 82.0M | 265M | 466M |
| Total Debt | 66.5M | 87.4M | 89.9M | 136M | 118M | 104M | 146M | 189M | 153M | 146M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 193M | 248M | 264M | 321M | 625M | 324M | 238M | 430M | 549M | 670M |
| Capital Expenditure | 68.6M | 105M | 139M | 171M | 185M | 170M | 211M | 339M | 103M | 175M |
| Free Cash Flow | 124M | -105M | 125M | -171M | -185M | -170M | -211M | 90.6M | 446M | 495M |
| Ratios | ||||||||||
| ROE | 23.5% | 23.6% | 22.0% | 29.5% | 34.5% | 22.4% | 14.3% | 7.5% | 20.0% | 22.1% |
| ROA | 17.7% | 17.5% | 16.6% | 20.0% | 25.3% | 17.9% | 11.4% | 5.8% | 14.8% | 16.4% |
| Net Profit Margin | 19.5% | 19.7% | 19.5% | 22.6% | 26.9% | 22.9% | 15.8% | 7.5% | 29.5% | 20.0% |
| Debt to Equity | 0.09x | 0.11x | 0.09x | 0.14x | 0.08x | 0.06x | 0.08x | 0.11x | 0.08x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fisher & Paykel Healthcare Corporation Limited dividends
- Dividend yield
- 1.10%
- Forward dividend
- 0.30 USD
- Payout ratio
- 53.9%
- Ex-dividend date
- Jun 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | NZD 255M | 0.43 | 53.9% |
| 2025 | NZD 196M | 0.33 | 51.9% |
| 2024 | NZD 146M | 0.25 | 109.7% |
| 2023 | NZD 196M | 0.34 | 78.2% |
| 2022 | USD 225M | 0.39 | 59.7% |
| 2021 | USD 181M | 0.31 | 34.6% |
| 2020 | USD 146M | 0.25 | 51.0% |
| 2019 | USD 119M | 0.21 | 57.1% |
| 2018 | USD 109M | 0.19 | 57.2% |
| 2017 | USD 97.3M | 0.17 | 57.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Oct 4, 2004.
Who owns Fisher & Paykel Healthcare Corporation Limited
- Insiders 3.69%
- Institutions 38.89%
- Public & others 57.42%
- Shares outstanding 588M
- Free float 585M
Fisher & Paykel Healthcare Corporation Limited company profile
- Company name
- Fisher & Paykel Healthcare Corporation Limited
- Ticker
- FSPKF.US
- ISIN
- NZFAPE0001S2
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 7,357
- Fiscal year end
- March
- Address
- 15 Maurice Paykel Place, Auckland, New Zealand, 2013
- Phone
- 64 9 574 0100
- Website
- fphcare.com
About Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Fisher & Paykel Healthcare Corporation Limited management
10- Mr. Lewis G. GradonMD, CEO & Executive Director · born 1961
- Ms. Lyndal YorkChief Financial Officer
- Mr. Andy NiccolChief Operating Officer
- Dr. Andrew SomervellVice President of Products & Technology
- Mr. Daniel AdolphHead of Investor Relations
- Ms. Raelene LeonardCompany Secretary & General Counsel
- Ms. Karen KnottGeneral Manager of Corporate Communications
- Mr. Justin CallahanVP of Sales & Marketing
- Ms. Nicola TalbotVice President of Human Resources
- Mr. Jonathan RhodesVice President ? Network Design, Facilities, Infrastructure & Sustainability